AIM ImmunoTech Inc. 8-K

What Happened
AIM ImmunoTech, Inc. (AIM) announced on June 15, 2026 (via Form 8-K and a press release) that it received a letter from NYSE Regulation on June 12, 2026 confirming the company has regained compliance with the NYSE American continued listing standards. The letter states AIM resolved previously identified deficiencies under Section 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide.

Key Details

• NYSE letter received June 12, 2026; press release attached to the 8-K dated June 15, 2026.
• NYSE confirmed compliance with the Part 10 continued listing standards and the specific Section 1003(a)(i),(ii),(iii) deficiencies were resolved.
• The “.BC” (below compliance) indicator will be removed from AIM’s trading symbol and AIM will be removed from NYSE American’s list of noncompliant issuers.
• AIM will remain subject to NYSE American’s ongoing monitoring procedures and reiterated its commitment to financial discipline and governance.

Why It Matters
Regaining compliance removes the formal “below compliance” indicator and the noncompliant listing designation, which can improve market perception and normal trading/reporting status for investors. However, the company remains under NYSE monitoring, so investors should continue to watch AIM’s future filings and disclosures for sustained compliance and operational updates. The 8-K also notes standard forward-looking statement cautions.